anti-PD-1 - Globe Thesis

Keyword [anti-PD-1] Result: 41 - 60 \| Page: 3 of 6
41.	Gut Microbiome Modulates Response To Anti-PD-1 Immunotherapy In Hepatobiliary Cancers
42.	Part 1:parallel Profiling Of Mutations And Methylation Changes From Bile Sample Detects Malignancies In Pancreatobiliary System Part 2:the Commensal Consortium Of The Gut Microbiome Is Associated With Favourable Responses To Anti-PD-1 Therapy In Patients
43.	The Efficacy Of Chemotherapy And Immunotherapy For Patients With Advanced Gastric Cancer And Colorectal Cancer And The Analyses Of Prognostic Factors
44.	Study On The Mechanism Of Gastric Cancer Mesenchymal Stem Cells Derived IL-8 Reducing The Efficacy Of Anti-PD-1 In Gastric Cancer
45.	Remodeling Chondroitin-6-sulfate-mediated Immune Exclusion Enhances Anti-PD-1 Response In Microsatellite-stable Colorectal Cancer
46.	Adverse Reaction Profile And Predictive Markers Of Anti-PD-1/PD-L1 Immunotherapy
47.	Tumor Immune Microenvironment Subtyping And Its Multi-omics Molecular Features In The Evaluation Of The Efficacy And Prognosis Of Anti-PD-1/PD-L1 Immunotherapy
48.	Secretions From Hypochlorous Acidtreated Tumor Cells Delivered In A Melittin Hydrogel Potentiate Cancer Immunotherapy
49.	Resistance To Anti-PD-1 Therapy Is Associated With The Retention Of CXCR3⁺ CD4⁺ CD8^- T Cells In Blood
50.	Anti-PD-1 Monoclonal Antibody Enhanced The Therapeutic Effects Of Melanoma Peptide Vaccine
51.	Predictive Value Of Peripheral Blood T Cell Invigoration On Anti-PD-1 Immune Efficacy In Patients With Advanced Tumors
52.	Combination Of EP And Anti-PD-1 Pathway Or Anti-CTLA-4 For The Phase Ⅲ Trial Of Small Cell Lung Cancer:A Meta-analysis
53.	The Effect Of Anti-PD-1 On Lung Cancer In Mice
54.	The Synergistic Anti-tumor Effect Of Iodine-125 Low-dose-rate Brachytherapy And Anti-PD-1 Therapy On Lung Cancer In Mice
55.	Safety And Efficacy Of Anti-PD-1/PD-l1 Antibodies In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma:a Meta-Analysis
56.	Preparation Of Shark Anti-PD-1 Single Domain Antibody And Preliminary Study On Anti-tumor Activity
57.	The Prognostic Value Of Peripheral Blood Inflammatory Markers In Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD-1 Immunotherapy
58.	Construction And Evaluation Of Anti-PD-1/PD-L1 Treatment Efficacy Prediction Model For Advanced Non-small Cell Lung Cancer
59.	Targeting CAMKⅡ To Reprogram Tumor-associated Macrophages And Inhibit Tumor Cells With An Injectable Hybrid Peptide Hydrogel
60.	Clinical Observation Of Skin-related Adverse Events Induced By Anti-PD-1 Antibody BGB-A317 In Patients With Solid Tumor
<<First <Prev Next> Last>> Jump to